Beactica Therapeutics AB, together with researchers at KU Leuven, has been awarded a €2.5 million (US$3.0 million) grant by the European Innovation Council (EIC) to advance BEA-17, a precision immune therapy for glioblastoma.
Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.
Biopharma and med-tech companies raising money in public or private financings, including: Berlin Heals, Biorestorative, Entirety, Nektar, Neupulse, Neurent, Xilio.
Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor.
Ascletis Pharma Inc. raised HK$843.53 million (US107.93 million) in a placement on the Hong Kong Stock Exchange to advance its lead program, ASC-30, a small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist that can be dosed once monthly subcutaneously and once daily orally for treating obesity.
RSS
.webp?height=488&t=1770931675&width=650 "Interleukin 17 (IL-17)")
